CXCL8 and triple-negative breast carcinoma: The results showed that tocilizumab significantly reduced IL-8 production in triple-negative breast cancer cells, and treated HUVEC cells exhibited a marked decrease in angiogenesis, as evidenced by the reduced tube formation in vitro.